Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

23:43 EST 2nd March 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 26,000+

Monday 2nd March 2015

Charles River Laboratories to Present at March Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Raymond James 36th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 3rd, at 11:35 a.m. ET; Cowen and Company 35th Annual Health Care Con...

Chamaeleo Pharma Appoints Han Van ‘t Klooster as Vice President of Commercial Operations

Diegem, Belgium, March 2, 2015 / B3C newswire / - Chamaeleo Pharma NV, a Belgium-based oncology company, announced today that Han Van ‘t Klooster has joined Chamaeleo as Vice President of Commercial Operations.  Han will be a member of Chamaeleo’s Management team and will be responsible for the market access and commercial launch of the Company’s lead product Fosfestrol for the treatme...

China frames a policy for hospital drug purchases

Biospectrum With a view to reduce corruption and safeguard public health, the Chinese Ministry has issued a policy stating that hospitals must purchase drug only from pr...

Dr. Julie Brahmer, MD, Named March LUNGevity Hero for Research in Groundbreaking Field of Immunotherapy

WASHINGTON, March 2, 2015 /PRNewswire-USNewswire/ -- To kick off Women in History month, LUNGevity Foundation announces Dr. Julie Brahmer, MD, as the March LUNGevity Hero for her work in the field of immunotherapy for lung cancer patients.  Dr. Brahmer is a vocal advocate for lung cancer research, passionate doctor and professor of oncology, and innovative researcher. Growing up in Nebraska...

Shire Submits Application For FDA Approval Of Lifitegrast For Dry Eye Disease

SAINT HELIER (dpa-AFX) - Shire plc (SHPG, SHPG.L) said it has submitted a New Drug Application or NDA with the U.S. Food and Drug Administration for its investigational compound Lifitegrast for th...

Sanofi's Toujeo heads latest crop of CHMP opinions

Sanofi's long-acting follow-up to blockbuster basal insulin Lantus has been recommended for approval in the EU, just a few days after getting a green light from the US FDA.Toujeo is a higher-strength formulation of $7 billion-a-year Lantus (insulin g...

Clearside Biomedical, Inc. Initiates Phase 2 Clinical Trial to Evaluate Reducing Treatment Visits While Improving Outcomes in Macular Edema Associated with Retinal Vein Occlusion

Follows the recent initiation of Clearside’s Phase 2 clinical trial for the treatment of macular edema associated with non-infectious uveitis Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the enrollment of the first patient in a Phase ...

Incyte Appoints Steven H. Stein, MD as Chief Medical Officer

Incyte Corporation (Nasdaq: INCY) announced today that Steven H. Stein, MD, has been appointed Senior Vice President and Chief Medical Officer, effective immediately. Dr. Stein was formerly SVP, US Clinical Development & Medical Affairs at Novartis Oncology US, and he will be responsible for clinical and medical strategy and operations across Incyte’...

Med Prep execs accused of lying about sterility practices at compounding facility

Med Prep Consulting execs committed fraud and violated the Federal Food, Drug and Cosmetic Act (FDCA) according to the US DoJ, which has accused the New Jersey compounder of knowingly selling drugs produced in unsanitary conditions.

UPDATE 1-FDA rejects Pacira's application for expanded use of pain drug

March 2 (Reuters) - The U.S. Food and Drug Administration rejected Pacira Pharmaceuticals Inc's application for expanding the use of its post-surgery pain drug, Exparel.

Basal cell carcinoma drug encourages both cancer regression and loss of taste in patients

Many patients undergoing chemotherapy experience severe taste disruptions that make eating a challenge at a time when maintaining good nutrition is extremely important. Now, researchers report that they have identified the pathway responsible for tas...

Compugen to Present at Two Oncology Conferences in March

Presentations include experimental data demonstrating potential of Compugen-discovered novel immune checkpoints as targets for cancer immunotherapy Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two oncology conferences this month. Galit Rotman, PhD, Chief Scientist...

New FDA official inherits raft of projects, challenges

One of the nation's leading medical researchers joined the Food and Drug Administration on Monday, taking on the agency's No. 2 leadership job at a critical juncture for prescription drugs, medical devices and tobacco products.

GSK has most to prove after $16 bn Novartis deal

The $16 billion dollar 'asset swap' deal between GlaxoSmithKline (GSK) and Novartis has been formally completed today, with the UK-headquartered company exchanging its oncology portfolio for the Swiss firm's vaccines business.The move allows both com...

China regulates hospital drug purchasing

A document on hospital drug purchasing in China was released Saturday, which instructed that hospitals…

Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer's Agitation, Depression and Other CNS Diseases

-- ALKS 7119 to Enter Clinic This Year; Joins Expanding CNS Pipeline Focused on Major Chronic Diseases -- -- Company to Provide Update at Analyst and Investor Event and Outline Commercial Potentia...

RPT-Companies' tests used in "superbug" scope cleaning flawed -FDA

March 2 (Reuters) - Manufacturers' tests of procedures to clean medical scopes linked with "superbug" outbreaks contained flaws that render their cleaning instructions unreliable, according to a senior official with the U.S. Food and Drug Administrat...

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML Consolidation Treatment

- BL-8040 Phase 2b study, as consolidation treatment for AML patients responding to standard induction treatment, is expected to commence shortly after receipt of regulatory approval, anticipated in next few months - BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licen

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

– Phase 2 data from luspatercept trials in β-thalassemia and MDS patients given as oral presentations at ASH and MDS abstract included in “Best of ASH” session – – Plans with Celgene to initiate phase 3 clinical trials in both β-thalassemia and MDS in 2015 – – Sotatercept slowed the progression of vascular calcification in...

Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer’s Agitation, Depression and Other CNS Diseases

–– ALKS 7119 to Enter Clinic This Year; Joins Expanding CNS Pipeline Focused on Major Chronic Diseases –– –– Company to Provide Update at Analyst and Investor Event and Outline Commercial Potential for Late-Stage CNS Portfolio –– Alkermes plc (NASDAQ: ALKS) today announced a new drug candidate, ALKS 7119, for th

Cardio3 BioSciences marks first important milestone in regulatory path toward C-Cure® market registration with Paediatric Investigation Plan waiver from EMA

MONT-SAINT-GUIBERT, Belgium, March 2, 2015 /PRNewswire/ -- Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of specialized cell therapies, today announced that it has received a Paediatric Investigation Plan (PIP) waiver from the European Medicines Agency (EMA) for C-Cure®, the Company's lead product-candidate currently in Phase II...

With Celiac Deal, Celimmune Aims to Give New Life to Old Amgen Drug

Sometimes a drug gathering dust at a big company finds new life at a startup. And sometimes the two companies cut a deal, in case that startup is on to something. That’s exactly what biotech giant Amgen is doing with brand-new startup Celimmune...

FDA rejects Pacira's application for expanded use of pain drug

(Reuters) - The U.S. Food and Drug Administration rejected Pacira Pharmaceuticals Inc's application for expanding the use of its pain drug, exparel.

Oncolytics soars on orphan designation for fallopian tube cancer

Shares of Oncolytics Biotech (TSE:ONC) (NASDAQ:ONCY) surged Monday after the US FDA granted the clinical-stage biotech company orphan drug designation for its lead product candidate Reolysin, for the treatment of fallopian tube cancer. The company ap...

Oscar Statue Snorting Cocaine Catches All Eyes in Hollywood, Ca

USA (PRWEB) March 02, 2015 A cocaine snorting Oscar statue in Hollywood is the newest scandal deviating from the typical nip slip or scathing scuffle. A new take on the glamour of the movie industry is dawning the streets of Hollywood as Paper Je...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks